Bridgeway Capital Management, LLC Metacrine, Inc. Transaction History

Bridgeway Capital Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.64 - $3.83 $60,544 - $362,318	-94,600 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.61 - $3.84 $39,150 - $57,600	15,000 Added 18.84%	94,600 $324,000
Q2 2021 Aug 16, 2021	SELL	$3.37 - $5.73 $185,350 - $315,150	-55,000 Reduced 40.86%	79,600 $302,000
Q1 2021 May 17, 2021	BUY	$6.2 - $11.0 $834,520 - $1.48 Million	134,600 New	134,600 $835,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.